DE69232925D1 - Angiostatische steroide - Google Patents

Angiostatische steroide

Info

Publication number
DE69232925D1
DE69232925D1 DE69232925T DE69232925T DE69232925D1 DE 69232925 D1 DE69232925 D1 DE 69232925D1 DE 69232925 T DE69232925 T DE 69232925T DE 69232925 T DE69232925 T DE 69232925T DE 69232925 D1 DE69232925 D1 DE 69232925D1
Authority
DE
Germany
Prior art keywords
disclosed
angiostatic steroids
ocular hypertension
neovascularization
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232925T
Other languages
English (en)
Other versions
DE69232925T2 (de
Inventor
F Clark
E Conrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/941,485 external-priority patent/US5371078A/en
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of DE69232925D1 publication Critical patent/DE69232925D1/de
Publication of DE69232925T2 publication Critical patent/DE69232925T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
DE69232925T 1991-11-22 1992-11-23 Angiostatische steroide Expired - Lifetime DE69232925T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79616991A 1991-11-22 1991-11-22
US89244892A 1992-06-02 1992-06-02
US07/941,485 US5371078A (en) 1988-10-31 1992-09-08 Angiostatic steroids and methods and compositions for controlling ocular hypertension
PCT/US1992/010133 WO1993010141A2 (en) 1991-11-22 1992-11-23 Angiostatic steroids

Publications (2)

Publication Number Publication Date
DE69232925D1 true DE69232925D1 (de) 2003-03-20
DE69232925T2 DE69232925T2 (de) 2003-06-18

Family

ID=27419924

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232925T Expired - Lifetime DE69232925T2 (de) 1991-11-22 1992-11-23 Angiostatische steroide

Country Status (10)

Country Link
EP (4) EP0614463B1 (de)
JP (1) JP3378245B2 (de)
AT (1) ATE232540T1 (de)
AU (1) AU678961B2 (de)
CA (4) CA2425846A1 (de)
DE (1) DE69232925T2 (de)
DK (1) DK0614463T3 (de)
ES (1) ES2187503T3 (de)
HK (4) HK1046370A1 (de)
WO (1) WO1993010141A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5969168A (en) * 1991-01-07 1999-10-19 Pherin Corporation Androstanes for inducing hypothalamic effects
DE4311987A1 (de) * 1993-04-07 1994-10-13 Schering Ag Neue Glucocorticoide
ES2210243T3 (es) * 1993-06-15 2004-07-01 Pherin Corporation Esteroides de androstano utiles como iniciadores del cambio de la funcion hipotalamica humana, composiciones farmaceuticas y procedimientos asociados.
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
WO1997041867A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
PT930876E (pt) 1996-07-22 2005-01-31 Renovo Ltd Utilizacao de moduladores da funcao esteroide sexual para tratar feridas e desordens fibroticas
AU1935501A (en) * 1999-12-09 2001-06-18 Alcon Universal Limited Id protein inhibitors for treating ocular diseases
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002040030A1 (en) * 2000-11-16 2002-05-23 Alcon Manufacturing, Ltd. Combination therapy for lowering and controlling intraocular pressure
DE60114229T2 (de) 2000-11-29 2006-07-06 Allergan, Inc., Irvine Verhinderung von transplantatabstossung im auge
EP1380302B1 (de) * 2001-03-28 2008-08-20 Santen Pharmaceutical Co., Ltd. Heilmittel für erkrankungen der retina und der aderhaut die als aktive bestandteile steroide enthalten
US20030119800A1 (en) * 2001-06-18 2003-06-26 Manolagas Stavros C. Bone anabolic compounds and methods of use
US20040214806A1 (en) 2002-09-03 2004-10-28 Iok-Hou Pang Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
TWI320712B (en) * 2001-09-05 2010-02-21 Alcon Inc The use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8081598B2 (en) 2003-02-18 2011-12-20 Qualcomm Incorporated Outer-loop power control for wireless communication systems
US8391249B2 (en) 2003-02-18 2013-03-05 Qualcomm Incorporated Code division multiplexing commands on a code division multiplexed channel
US7155236B2 (en) 2003-02-18 2006-12-26 Qualcomm Incorporated Scheduled and autonomous transmission and acknowledgement
US7660282B2 (en) 2003-02-18 2010-02-09 Qualcomm Incorporated Congestion control in a wireless data network
US20040160922A1 (en) 2003-02-18 2004-08-19 Sanjiv Nanda Method and apparatus for controlling data rate of a reverse link in a communication system
US8023950B2 (en) 2003-02-18 2011-09-20 Qualcomm Incorporated Systems and methods for using selectable frame durations in a wireless communication system
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
US7215930B2 (en) 2003-03-06 2007-05-08 Qualcomm, Incorporated Method and apparatus for providing uplink signal-to-noise ratio (SNR) estimation in a wireless communication
US8705588B2 (en) 2003-03-06 2014-04-22 Qualcomm Incorporated Systems and methods for using code space in spread-spectrum communications
EP2301549A1 (de) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Mittel zur Behandlung von Krankheiten zur Aufbringung auf das Auge
WO2004093882A1 (ja) * 2003-04-18 2004-11-04 Advanced Medicine Research Institute 眼に適用する疾患治療剤
US8477592B2 (en) 2003-05-14 2013-07-02 Qualcomm Incorporated Interference and noise estimation in an OFDM system
US7315527B2 (en) 2003-08-05 2008-01-01 Qualcomm Incorporated Extended acknowledgement and rate control channel
US8489949B2 (en) 2003-08-05 2013-07-16 Qualcomm Incorporated Combining grant, acknowledgement, and rate control commands
US20050239760A1 (en) * 2004-04-23 2005-10-27 Alcon, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2006002907A1 (en) * 2004-06-29 2006-01-12 Jadolabs Gmbh Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts
ES2447025T3 (es) * 2005-07-12 2014-03-11 Ampio Pharmaceuticals, Inc. Métodos y productos para el tratamiento de enfermedades
CN103739647B (zh) 2008-05-28 2017-06-09 雷沃根生物医药有限公司 用于治疗疾病的NF‑κB的非激素甾体调节剂
PL2554172T3 (pl) 2009-06-22 2015-03-31 Ampio Pharmaceuticals Inc Sposób leczenia chorób
EP2556083A4 (de) 2010-04-05 2013-12-04 Validus Biopharma Inc Nichthormonale steroide modulatoren von nf-kappa-b zur krankheitsbehandlung
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
SG11201508071VA (en) 2013-03-29 2015-10-29 Biomed Valley Discoveries Inc C. novyi for the treatment of solid tumors in humans
US11033621B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
EP3250562A4 (de) 2015-01-30 2018-07-11 Biomed Valley Discoveries, Inc. Kristalline formen von c21h22ci2n4o2
CA2975116C (en) 2015-01-30 2022-10-11 Biomed Valley Discoveries, Inc. Crystalline c21h22c12n4o2 malonate
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB790452A (en) * 1955-04-01 1958-02-12 Upjohn Co Steroids and the preparation thereof
US3658856A (en) * 1969-09-02 1972-04-25 Syntex Corp Process for preparing useful 17alpha-hydroxy-20-keto-21-acyloxy pregnanes
US4041055A (en) * 1975-11-17 1977-08-09 The Upjohn Company Process for the preparation of 17α-hydroxyprogesterones and corticoids from androstenes
US4342702A (en) * 1981-05-18 1982-08-03 The Upjohn Company Metallated halogenated acetylene corticoid synthesis
US4357279A (en) * 1981-05-18 1982-11-02 The Upjohn Company Preparation of corticoids from 17-keto steroids
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4600538A (en) * 1984-08-02 1986-07-15 The Upjohn Company Corticosteroids from 17-keto steroids via 20-cyano-Δ17 (20)-pregnanes
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
DE3680788D1 (de) * 1985-10-23 1991-09-12 Upjohn Co Angiostatische steroide.
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US5036048A (en) * 1986-03-07 1991-07-30 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
DE3878463T2 (de) * 1987-08-14 1993-06-24 Upjohn Co Verfahren zur 9-alpha-dehalogenierung von 9-alpha-steroiden.
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
JPH04506066A (ja) * 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
JPH05500054A (ja) * 1989-08-28 1993-01-14 アルコン　ラボラトリーズ　インコーポレイテッド 眼科組成物
JP2985007B2 (ja) * 1990-02-09 1999-11-29 武田薬品工業株式会社 血管新生阻害剤
AU657690B2 (en) * 1990-06-11 1995-03-23 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis

Also Published As

Publication number Publication date
ES2187503T3 (es) 2003-06-16
HK1012638A1 (en) 1999-08-06
ATE232540T1 (de) 2003-02-15
CA2425849A1 (en) 1993-05-27
EP1236469A3 (de) 2004-09-01
EP0614463B1 (de) 2003-02-12
AU3223593A (en) 1993-06-15
EP1236470A2 (de) 2002-09-04
EP1236471A2 (de) 2002-09-04
EP1236469A2 (de) 2002-09-04
WO1993010141A2 (en) 1993-05-27
HK1046371A1 (zh) 2003-01-10
WO1993010141A3 (en) 1993-09-02
CA2425841A1 (en) 1993-05-27
HK1046369A1 (zh) 2003-01-10
CA2123405A1 (en) 1993-05-27
JPH07501081A (ja) 1995-02-02
JP3378245B2 (ja) 2003-02-17
HK1046370A1 (zh) 2003-01-10
EP1236471A3 (de) 2004-12-15
CA2123405C (en) 2008-01-15
CA2425841C (en) 2006-01-10
EP0614463A1 (de) 1994-09-14
CA2425846A1 (en) 1993-05-27
DE69232925T2 (de) 2003-06-18
AU678961B2 (en) 1997-06-19
EP1236470A3 (de) 2004-09-01
DK0614463T3 (da) 2003-03-31
CA2425849C (en) 2007-02-27

Similar Documents

Publication Publication Date Title
DE69232925D1 (de) Angiostatische steroide
DK542989A (da) Praeparat til bekaempelse af ocular hypertension
AU7748898A (en) Use of cloprostenol, fluprostenol and their analogues to treat glaucoma and ocular hypertension
EP1225168B8 (de) Prostaglandin-F-2-alpha Derivat zur Behandlung von Glaukom und Augenhochdruck
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
CA2315829A1 (en) Angiostatic agents and compositions for controlling ocular hypertension
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
EP0489779A4 (en) Ophthalmic composition
ATE251905T1 (de) Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien
WO2002040030A8 (en) Combination therapy for lowering and controlling intraocular pressure
DK0650496T3 (da) Anti-inflammatoriske forbindelser til oftalmisk anvendelse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition